, Volume 65, Issue 9, pp 1193–1206 | Cite as

Use of Antipsychotics in the Management of Schizophrenia during Pregnancy

  • Mátyás TrixlerEmail author
  • Ágnes Gáti
  • Sándor Fekete
  • Tamás Tényi
Therapy in Practice


The rapid development of pharmacotherapy has resulted in a growing clinical importance for the treatment of the increasing number of women with schizophrenia during pregnancy. An evolving database on reproductive health safety factors for women with schizophrenia has begun to be of assistance in optimising clinical benefits for women with childbearing potential.

Given the prevalence of antipsychotic use during pregnancy in women with schizophrenia, it is important for the clinician to have a prepared approach to the administration of these agents. In general, the use of psychotropic medication during pregnancy is indicated when risk to the fetus from exposure to this medication is outweighed by the risks of untreated psychiatric illness in the mother. The preponderance of evidence from registries to large health surveys indicate that treatment with antipsychotic medication confers either no or a small nonspecific risk for organ malformations.

According to the relevant literature published on the safety of antipsychotic medication during pregnancy, the findings are encouraging; however, the currently available data are very limited. Until there are more controlled prospective data on the impact of drugs on fetal and later development, the clinician will continue to work in a state of potential uncertainty, weighing partially estimated risks against managing individual clinical problems. The aim for the clinician should be to provide the best information available regarding the scope of possible risks associated with the treatment of schizophrenia during pregnancy. On the basis of the available data, generalisation is impossible and recommendations should be made on a drug-by-drug basis. The risks and benefits must always be carefully weighed for each patient on an individual basis. Only a woman who is well enough to acknowledge her pregnancy and her mental illness can effectively weigh the relative and partially unknown risks of treatment with antipsychotic medication against the highly probable risks of illness exacerbation if untreated.


Schizophrenia Haloperidol Clozapine Risperidone Olanzapine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



No sources of funding were used to assist in the preparation of this manuscript. The authors have no conflicts of interest that are directly relevant to the content of this review.


  1. 1.
    Stevens BC. Psychoses associated with childbirth: a demographic survey since the development of community care. Soc Sci Med 1971; 5: 527–9PubMedCrossRefGoogle Scholar
  2. 2.
    Trixler M, Gáti Á, Tényi T. Risks associated with childbearing in schizophrenia. Acta Psychiatr Belg 1995; 95: 159–62PubMedGoogle Scholar
  3. 3.
    Bratfos O, Haug JI. Puerperal mental disorders in manic-depressive females. Acta Psychiatr Scand 1966; 42: 285–8PubMedCrossRefGoogle Scholar
  4. 4.
    Reich T, Winokur G. Postpartum psychoses in patients with manic-depressive disease. J Nerv Ment Dis 1970; 151: 60–4PubMedCrossRefGoogle Scholar
  5. 5.
    McKenna K, Einarson A, Levinson A, et al. Significant changes in antipsychotic drug use during pregnancy. Vet Hum Toxicol 2004; 46: 44–6PubMedGoogle Scholar
  6. 6.
    Reynolds R. The effects on the infant of psychotropic drugs used in pregnancy. In: Krauer B, Krauer F, Hytten FE, et al., editors. Drugs in pregnancy: maternal drug handling, fetal drug exposure. London: Academic Press, 1984: 131–50Google Scholar
  7. 7.
    Goldberg HL, Nissim R. Psychotropic drugs in pregnancy and lactation. Int J Psychiatr Med 1994; 24: 129–49CrossRefGoogle Scholar
  8. 8.
    Lewis P. Drug usage in pregnancy. In: Lewis P, editor. Clinical pharmacology in obstetrics. Boston (MA): Wright-PSG, 1983Google Scholar
  9. 9.
    Bennedsen BE, Mortensen PB, Olesen AV, et al. Congenital malformations, stillbirths, and infant deaths among children of women with schizophrenia. Arch Gen Psychiatry 2001; 58: 674–9PubMedCrossRefGoogle Scholar
  10. 10.
    Sitland-Marken P, Rickman LA, Wells BG, et al. Management of acute mania in pregnancy. J Clin Psychopharmacol 1989; 9: 78–87PubMedCrossRefGoogle Scholar
  11. 11.
    Mortola J. The use of psychotropic agents in pregnancy and lactation. Psychiatr Clin North Am 1989; 12: 69–87PubMedGoogle Scholar
  12. 12.
    Altshuler LL, Cohen L, Szuba MP, et al. Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. Am J Psychiatry 1996; 153: 592–606PubMedGoogle Scholar
  13. 13.
    Sobel DE. Fetal damage due to ECT, insulin coma, chlorpromazine or reserpine. Arch Gen Psychiatry 1960; 2: 606–11CrossRefGoogle Scholar
  14. 14.
    Rieder O, Rosenthal D, Wender P, et al. The off-spring of schizophrenics: fetal and neonatal death. Arch Gen Psychiatry 1975; 32: 200–11PubMedCrossRefGoogle Scholar
  15. 15.
    Edlund MJ, Craig TJ. Antipsychotic drug use and birth defects: an epidemiologic reassessment. Compr Psychiatry 1984; 25: 32–8PubMedCrossRefGoogle Scholar
  16. 16.
    Ayd FJ. Haloperidol: 15 years of clinical experience. Dis Nerv Syst 1972; 33: 459–69PubMedGoogle Scholar
  17. 17.
    Guze BH, Guze PA. Psychotropic medication use during pregnancy. West J Med 1989; 151: 296–8PubMedGoogle Scholar
  18. 18.
    Dieulangard P, Coignet J, Vidal JC. Sur un cas d’ectrophocomélie peut-être d’origine médicamenteuse. Bull Féd Gynécol Obstét 1966; 18: 85–7Google Scholar
  19. 19.
    Kopelman AE, McCullar FW, Heggeness L. Limb malformations following maternal use of haloperidol. JAMA 1975; 231: 62–4CrossRefGoogle Scholar
  20. 20.
    Hanson JW, Oakley Jr GP. Haloperidol and limb deformity [letter]. JAMA 1975; 231: 26PubMedCrossRefGoogle Scholar
  21. 21.
    Godet PF, Marie-Cardine M. Neuroleptiques, schizophrenie et grossesse: etude epidemiologique et teratologique. Encephale 1991; 17: 543–7PubMedGoogle Scholar
  22. 22.
    Lieberman J, Safferman AZ. Clinical profile of clozapine: adverse reactions and agranulocytosis. In: Jones LY, editor. Clozapine in treatment resistant schizophrenia: a scientific update. London: Royal Society of Medicine, 1992Google Scholar
  23. 23.
    Koren G, Cohn T, Chitayat D, et al. Use of atypical antipsychotics during pregnancy and the risk of neural tube defects in infants. Am J Psychiatry 2002; 159: 136–7PubMedCrossRefGoogle Scholar
  24. 24.
    Dickson RA, Edwards A. Clozapine and fertility. Am J Psychiatry 1997; 154: 582–3PubMedGoogle Scholar
  25. 25.
    Tényi T, Trixler M. Clozapine in the treatment of pregnant schizophrenic women. Psychiatria Danubina 1998; 10: 15–8Google Scholar
  26. 26.
    Dickson RA, Hogg L. Pregnancy of a patient treated with clozapine. Psychiatr Serv 1998; 49: 1081–3PubMedGoogle Scholar
  27. 27.
    DiMichele V, Ramenghi LA, Sabatino G. Clozapine and lorazepam administration in pregnancy [letter]. Eur Psychiatry 1996; 11: 214CrossRefGoogle Scholar
  28. 28.
    Stones SC, Sommi Jr RW, Rasken PA, et al. Clozapine use in two full-term pregnancies [letter]. J Clin Psychiatry 1997; 58: 364–5CrossRefGoogle Scholar
  29. 29.
    Tényi T, Trixler M, Vereczkey G, et al. Use of clozapine during pregnancy [in Hungarian]. Orv Hetil 1994; 135: 1967–9PubMedGoogle Scholar
  30. 30.
    Waldman MD, Safferman AZ. Pregnancy and clozapine [letter]. Am J Psychiatry 1993; 150: 168–9PubMedGoogle Scholar
  31. 31.
    Dev V, Krupp P. The side-effects and safety of clozapine. Rev Contemp Pharmacother 1995; 6: 197–208Google Scholar
  32. 32.
    Nguyen HN, Lalonde P. Clozapine et grossesse. Encephale 2003; 29: 119–24PubMedGoogle Scholar
  33. 33.
    Goldstein DJ, Corbin LA, Fung MC. Olanzapine-exposed pregnancies and lactation: early experience. J Clin Psychopharmacol 2000; 20: 399–403PubMedCrossRefGoogle Scholar
  34. 34.
    Lilly Research Laboratories, Lilly Corporate Center. Written correspondence at 2004 Mar 10. Indianapolis (IN): Eli Lilly & Company, 2004. (Data on file)Google Scholar
  35. 35.
    McDonald AD. Maternal health and congenital defect: a prospective investigation. N Engl J Med 1958; 258: 767–73PubMedCrossRefGoogle Scholar
  36. 36.
    Kerly M. Reproductive and perinatal epidemiology. Boca Raton (FL): CRC Press, 1999: 69Google Scholar
  37. 37.
    Patton SW, Misri S, Corral MR, et al. Antipsychotic medication during pregnancy and lactation in women with schizophrenia: evaluating the risk. Can J Psychiatry 2002; 47: 9559–65Google Scholar
  38. 38.
    Nagy A, Tényi T, Lénárd K, et al. Olanzapine and pregnancy [in Hungarian]. Orv Hetil 2001; 142: 137–8PubMedGoogle Scholar
  39. 39.
    Kirchheiner J, Berghofer A, Bolk-Weischedel D. Healthy outcome under olanzapine treatment in a pregnant woman. Pharmacopsychiatry 2000; 33: 78–80PubMedCrossRefGoogle Scholar
  40. 40.
    Neumann NU, Frasch K. Olanzapine and pregnancy: 2 case reports [in German]. Nervenarzt 2001; 72: 876–8PubMedCrossRefGoogle Scholar
  41. 41.
    Littrell KH, Johnson CG, Peabody CD, et al. Antipsychotics during pregnancy [letter]. Am J Psychiatry 2000; 157: 1342PubMedCrossRefGoogle Scholar
  42. 42.
    Ratnayake T, Libretto SE. No complications with risperidone treatment before and throughout pregnancy and during the nursing period. J Clin Psychiatry 2002; 63: 76–7PubMedCrossRefGoogle Scholar
  43. 43.
    MacKay FJ, Wilton GL, Pearce SN, et al. The safety of risperidone a post-marketing study on 7684 patients. Hum Psychopharmacol Clin Exp 1998; 13: 413–8CrossRefGoogle Scholar
  44. 44.
    Tényi T, Trixler M, Keresztes ZS. Quetiapine and pregnancy [letter]. Am J Psychiatry 2002; 159: 674PubMedCrossRefGoogle Scholar
  45. 45.
    Taylor TM, O’Toole MS, Ohlsen RI, et al. Safety of quetiapine during pregnancy [letter]. Am J Psychiatry 2003; 160: 588–9PubMedCrossRefGoogle Scholar
  46. 46.
    Food and Drug Administration. Labeling and prescription drug advertising: content and format for labeling for human prescription drugs. Fed Regist 1979; 44: 37434–67Google Scholar
  47. 47.
    Ernst CL, Goldberg JF. The reproductive safety profile of mood stabilizers, atypical antipsychotics, and broad-spectrum psychotropics. J Clin Psychiatry 2002; 63 Suppl. 4: 42–55PubMedGoogle Scholar
  48. 48.
    Hill RM, Desmond MM, Kay JK. Extrapyramidal dysfunction in an infant of a schizophrenic mother. J Pediatr 1966; 69: 589–95PubMedCrossRefGoogle Scholar
  49. 49.
    Tamer A, McKey R, Arias D, et al. Phenothiazine induced extrapyramidal dysfunction in the neonate. J Pediatr 1969; 75: 479–80PubMedCrossRefGoogle Scholar
  50. 50.
    Auerbach JG, Hans SL, Marcus J, et al. Maternal psychotropic medication and neonatal behavior. Neurotoxicol Teratol 1992; 14: 399–406PubMedCrossRefGoogle Scholar
  51. 51.
    Rayburn WF, Andresen BD. Principles of perinatal pharmacology. In: Rayburn WF, Zuspan FP, editors. Drug therapy in obstetrics and gynecology. Norwalk (CT): Appleton, Century, Crofts, 1982: 1–8Google Scholar
  52. 52.
    Desmond MM, Rudolph AJ, Hill RM, et al. Behavior alterations in infants born to mothers on psychoactive medication during pregnancy. In: Farrel G, editor. Congenital mental retardation. Austin (TX): University of Texas Press, 1967: 235–44Google Scholar
  53. 53.
    Hammond JE, Toseland PA. Placental transfer of chlorpromazine. Arch Dis Child 1970; 45: 139–40PubMedCrossRefGoogle Scholar
  54. 54.
    L’Hirondel J, Venzia R, Russelot P, et al. Ictere neonatal á la chlorpromazine. Arch Franc Péd 1968; 25: 1171–7Google Scholar
  55. 55.
    Clark CVH, Gorman D, Vernadakis A. Effects of prenatal administration of psychotropic drugs on behavior of developing rats. Dev Psychobiol 1970; 3: 225–35PubMedCrossRefGoogle Scholar
  56. 56.
    Golub M, Kornetsky C. Seizure susceptibility and avoidance conditioning in adult rats treated prenatally with chlorpromazine. Dev Psychobiol 1974; 7: 79–88PubMedCrossRefGoogle Scholar
  57. 57.
    Spear IP, Shalaby IA, Brick J. Chronic administration of haloperidol during development: behavioral and psychopharmacological effects. Psychopharmacology (Berl) 1980; 70: 47–58CrossRefGoogle Scholar
  58. 58.
    Kris EB. Children of mothers maintained on pharmacotherapy during pregnancy and postpartum. Curr Ther Res 1965; 7: 785–9PubMedGoogle Scholar
  59. 59.
    Stika L, Elisova K, Honzakova L, et al. Effects of drug administration in pregnancy on children’s school behaviour. Pharm Weekbl Sci 1990; 12: 252–5PubMedCrossRefGoogle Scholar
  60. 60.
    Pearson KH, Nonacs R, Cohen LS. Practical guidelines for the treatment of psychiatric disorders during pregnancy. In: Pearson KH, Sonawalla SB, Rosenbaum JF, editors. Women’s health and psychiatry. Philadelphia (PA): Lippincott Williams &Wilkins, 2002: 115–25Google Scholar
  61. 61.
    Viguera AC, Baldessarini RJ, Hegarty JD, et al. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch Gen Psychiatry 1997; 54: 49–55PubMedCrossRefGoogle Scholar
  62. 62.
    Dencker SJ, Malm U, Lepp M. Schizophrenic relapse after drug withdrawal is predictable. Acta Psychiatr Scand 1986; 73: 181–5PubMedCrossRefGoogle Scholar
  63. 63.
    Carpenter Jr WT, Hanlon TE, Heinrichs DW, et al. Continuous versus targeted medication in schizophrenic outpatients: outcome results. Am J Psychiatry 1990; 147: 1138–48PubMedGoogle Scholar
  64. 64.
    Baldessarini RJ, Viguera AC. Neuroleptic withdrawal in schizophrenic patients. Arch Gen Psychiatry 1995; 52: 189–92PubMedCrossRefGoogle Scholar
  65. 65.
    Gilbert PL, Harris MJ, McAdams LA, et al. Neuroleptic withdrawal in schizophrenic patients: a review of the literature. Arch Gen Psychiatry 1995; 52: 173–88PubMedCrossRefGoogle Scholar
  66. 66.
    Casiano ME, Hawkins DR. Major mental illness and childbearing: a role for the consultation-liaison psychiatrist in obstetrics. Psychiatr Clin North Am 1987; 10: 37–51Google Scholar
  67. 67.
    Miller LJ. Clinical strategies for the use of psychotropic drugs during pregnancy. Psychiatry Med 1991; 9: 275–98Google Scholar
  68. 68.
    Bernstein JG. Psychotropic drugs in pregnancy and lactation. In: Bernstein JG, editor. Handbook of drug therapy in psychiatry. 3rd ed. St Louis (MO): Mosby-Year Book Inc., 1995: 397–412Google Scholar
  69. 69.
    Trixler M, Tényi T. Antipsychotic use in pregnancy: what are the best treatment options? Drug Saf 1997; 16: 403–10PubMedCrossRefGoogle Scholar
  70. 70.
    Wadhwa PD, Sandman CA, Garite TJ. The neurobiology of stress in human pregnancy: implications for prematurity and development of the fetal central nervous system. In: Russell JA, Douglas AJ, Windle RJ, et al., editors. The maternal brain: neurobiological and neuroendocrine adaptation and disorders in pregnancy and post partum. Amsterdam: Elsevier, 2001: 131–42Google Scholar
  71. 71.
    Zuckerman B, Amaro H, Bauchner H, et al. Depressive symptoms during pregnancy: relationship to poor health behaviors. Am J Obstet Gynecol 1989; 160: 1107–11PubMedGoogle Scholar
  72. 72.
    Weinberg M, Tronick E. The impact of maternal psychiatric illness on infant development. J Clin Psychiatry 1998; 59: 63–71Google Scholar
  73. 73.
    Codero JF, Oakley GP. Drug exposure during pregnancy: some epidemiologic considerations. Clin Obstet Gynecol 1983; 26: 418–28CrossRefGoogle Scholar
  74. 74.
    Stowe ZN, Nemeroff CB. Psychopharmacology during pregnancy and lactation. In: Schatzberg AF, Nemeroff CB, editors. Textbook of psychopharmacology. Washington, DC: American Psychiatric Press, 1998: 979–96Google Scholar
  75. 75.
    Spielvogel A, Wile J. Treatment and outcomes of psychotic patients during pregnancy and childbirth. Birth 1992; 19: 131–7PubMedCrossRefGoogle Scholar
  76. 76.
    Hendrick V, Altshuler L, Cohen L, et al. Evaluation of mental health and depression during pregnancy: position paper. Psychopharmacol Bull 1998; 34: 297–9PubMedGoogle Scholar
  77. 77.
    Cohen LS. Psychotropic drug use in pregnancy. Hosp Community Psychiatry 1989; 40: 566–7PubMedGoogle Scholar
  78. 78.
    Werler MM, Louik C, Shapiro S, et al. Pre-pregnancy weight in relation to risk of neural tube defects. JAMA 1996; 275: 1089–92PubMedCrossRefGoogle Scholar
  79. 79.
    Shaw GM, Velie EM, Schaffer D. Risk of neural tube defectaffected pregnancies among obese women. JAMA 1996; 275: 1093–6PubMedCrossRefGoogle Scholar
  80. 80.
    Llewellyn A, Stove ZN, Strader Jr JR. The use of lithium and management of women with bipolar disorder during pregnancy and lactation. J Clin Psychiatry 1998; 59 Suppl. 6: 57–64PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  • Mátyás Trixler
    • 1
    Email author
  • Ágnes Gáti
    • 1
  • Sándor Fekete
    • 1
  • Tamás Tényi
    • 1
  1. 1.Department of PsychiatryUniversity Medical School of PécsPécsHungary

Personalised recommendations